Home Featured Page 6

Featured

Latest

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

The Psychedelic News Feed: January 5 – June 1, 2025

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at Burning Man

Dreamshadow Transpersonal Breathwork

East Forest IN THE PORTAL DOME

An Ecstatic Dance Experience IN THE PORTAL DOME

Samskara Film & Discussion w/ Android Jones IN THE PORTAL DOME

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major...

Jeff Breau – Exploring Psychedelic Churches at Harvard Divinity School

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

1...567...294 Page 6 of 294

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as...

The Psychedelic News Feed: January 5 – June 1, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

The Psychedelic News Feed: January 5 – June 1, 2025

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at Burning Man

Dreamshadow Transpersonal Breathwork

East Forest IN THE PORTAL DOME

SNOW RAVEN IN THE PORTAL DOME

PORTAL LATE-NIGHT TAKEOVER

An Ecstatic Dance Experience IN THE PORTAL DOME

Samskara Film & Discussion w/ Android Jones IN THE PORTAL DOME

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major...

Jeff Breau – Exploring Psychedelic Churches at Harvard Divinity School

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

EDITOR PICKS

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as...

The Psychedelic News Feed: January 5 – June 1, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY